This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Friday's Health Winners & Losers

Health stocks met the weekend on a mixed note Friday after another week of earnings and a day of analyst adjustments.

On Friday the Nasdaq and Amex biotechnology indices were down 0.6% and 1.1%, respectively. But the Amex pharmaceutical index nudged up 1.08, or 0.35%, to 306.61. Some of the pharmas on the uptick Friday included Bristol-Myers Squibb (BMY) and Wyeth (WYE), which increased 1.3% and 1.2%.

One offender to the Nasdaq biotech index Friday, Discovery Labs (DSCO), was brushed off by the Food and Drug Administration for a third time. The agency didn't approve its Surflaxin, a treatment for the prevention of respiratory distress syndrome (RDS) in premature infants, but said it could be approvable in the future if certain, undisclosed, conditions are met. Shares sank $1.40, or 48.2%, to $1.50. The company said investors can expect an update from the company early next week.

Other stocks moved on post-earnings analyst adjustments.

Vanda Pharmaceuticals (VNDA) shares traded higher, a day after its earnings. Caris began coverage of the company with a buy rating and a $22 price target, expecting a positive FDA decision for schizophrenia treatment Fanapta in July. Shares were up 50 cents, or 13.8%, to $4.12.

Meanwhile, JMP Securities downgraded Cerus (CERS) to market perform from market outperform, a day after its earnings. Cerus shares were off by 10.6%, at $5.63.

A day after posting its quarterly figures, Sepracor (SEPR) was also on the downtick amid analyst actions. Friedman Billings Ramsey downgraded the stock to underperform from market perform and dropped its price target to $17 from $23. Susquehanna Financial, which has a negative rating for the stock, upped its target to $17 from $14. Sepracor shares were down $1.90, or 8.8%, at $19.55.

And finally, Lazard Capital downgraded Palomar Medical Technologies (PMTI) a day after earnings to hold from buy. Its shares gave up $1.08, or 9%, to $10.91.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs